|
|
|
| Correlation study of serum ProGRP, NSE levels with chemotherapy efficacy and prognosis in patients with small cell lung cancer |
| HUANG Yuandong1 HE Lang1 ZHAO Xiaoping2 ZHANG Sheng1 XU Yi1 |
1.Department of Oncology, Chengdu Fifth People′s Hospital, Sichuan Province, Chengdu 611130, China;
2.Department of Respiratory, Chengdu Fifth People′s Hospital, Sichuan Province, Chengdu 611130, China |
|
|
|
Abstract Objective To investigate the relationship of serum levels of pro-gastrin-releasing peptide (ProGRP) and neuron-specific enolase (NSE) with chemotherapy efficacy and prognosis in patients with small cell lung cancer (SCLC). Methods A total of 103 SCLC patients who met the diagnostic criteria diagnosed in Oncology and Respiratory Department of Chengdu Fifth People′s Hospital from February 2016 to February 2017 were selected as study objects. Two cycles or more of the standard chemotherapy regimens were given to them. Serum ProGRP level was measured by enzyme-linked immunosorbent assay (ELISA), and serum NSE level was measured by electrochemiluminescence immunoassay (ECLIA). Taking the median serum ProGRP and NSE level as the boundary, the objects were divided into high ProGRP level group and low ProGRP level group, high NSE level group and low NSE level group, the relationship of the two indexes with efficacy and prognosis was analyzed. Results The serum levels of ProGRP and NSE in SCLC patients with tumor diameter ≥4 cm, extensive metastasis, distant metastasis and smoking history were higher than those in SCLC patients with tumor diameter ＜4 cm, limited clinical stage, no distant metastasis and no smoking history (P ＜ 0.05). The chemotherapeutic efficacy of low ProGRP level group was higher than that of high ProGRP level group, and PFS of low NSE level group was higher than that of high NSE level group. The factors affecting the prognosis of SCLC patients were clinical stage (OR = 4.986, 95%CI: 3.774-9.876, P = 0.003), distant metastasis (OR = 3.659, 95%CI: 2.182-7.569, P = 0.016) and serum NSE (OR = 2.879, 95%CI: 1.487-6.721, P = 0.005). Conclusion Serum ProGRP can predict the clinical efficacy of SCLC patients, serum NSE can predict the prognosis of SCLC patients. Two indicators should be evaluated comprehensively in clinical treatment, and close attention should be paid to SCLC patients with distant metastasis or extensive clinical stage.
|
|
|
|
|
|
[1] 王伙刚，洪波，林文楚.小细胞肺癌靶向治疗研究进展[J].中国药理学通报，2017，33（10）：1333-1337.
[2] 赵红峥，李燕，冯军花，等.NSE、ProGRP、Ki-67、TTF-1对小细胞肺癌诊断价值的研究[J].国际检验医学杂志，2018，39（3）：281-285.
[3] 陈阳阳，张洁，徐国宾.晚期肺癌患者一线化疗后6种血清肿瘤标志物水平的变化及意义[J].临床检验杂志，2015， 33（2）：124-129.
[4] 周际昌.实用肿瘤内科学[M].2版.北京：人民卫生出版社，2003：152-153.
[5] 陈克能.小细胞肺癌与TNM分期[J].中国肺癌杂志，2016， 19（6）：409-412.
[6] Eisenhauer EA，Therasse P，Bogaerts J，et al. New response evaluation criteria in solid tumours：revised RECIST guideline（version 1.1）[J]. Eur J Cancer，2008，45（2）：228-247.
[7] 黄宗华，徐丹丹，张飞艳，等.血清ProGRP和NSE对评价小细胞肺癌化疗疗效及其预后的价值[J].中华肿瘤防治杂志，2015，22（22）：1774-1778.
[8] Tamura M，Matsumoto I，Saito D，et al. Lymph node ratio as a prognostic factor in patients with small cell lung cancer [J]. World J Surg Oncol，2016，14（1）：295.
[9] 廖嘉煦，杨汉丰，肖应全，等.肺小细胞肺癌：流行病学、临床、病理、基因、影像学表现及治疗进展[J].中华临床医师杂志：电子版，2013，7（19）：8849-8851.
[10] 范新华，孟爽，张洪彬.小细胞肺癌的CT征象特点分析[J].医学影像学杂志，2015，25（2）：234-237.
[11] 努尔兰，余莹莹，韩文广，等.中央型肺鳞癌、小细胞肺癌CT征象与血清肿瘤标志物的关系及联合诊断的价值[J].中国CT和MRI杂志，2015，13（9）：57-61.
[12] 张淑艳，胡晓芳.NSE和ProGRP联合检测在小细胞肺癌中的应用价值[J].中国热带医学，2015，15（4）：466-468，476.
[13] Zhou Y，Liao Q，Han Y，et al. Rac1 overexpression is correlated with epithelial mesenchymal transition and predicts poor prognosis in small cell lung cancer [J]. J Cancer，2016，7（14）：2100-2109.
[14] 金霞霞，陈世勇，齐娟飞，等.血清NSE、ProGRP、CEA、SCCA和CYFRA21-1联检在肺癌诊断中的意义[J].放射免疫学杂志，2012，25（1）：83-86.
[15] 梁子坤，陈燕，荣长利，等.小细胞肺癌患者血清胃泌素释放肽前体检测的临床意义[J].国际检验医学杂志，2016，37（13）：1765-1766，1769.
[16] 王浩，田田，李家军，等.NSE与proGRP单独或并联联合检测对SCLC诊断价值的系统评价[J].肿瘤学杂志，2017，23（9）：765-771.
[17] Michels S，Wolf J. Stratified Treatment in Lung Cancer [J]. Oncol Res Treat，2016，39（12）：760-766.
[18] 王洪玲，李琳，王键玮，等.小细胞肺癌预后因子的研究进展[J].中国医药导报，2017，14（12）：56-59.
[19] 李岸凤，赵咏梅，刘运秋.NSE和ProGRP表达水平与小细胞肺癌病理分期的相关性研究[J].实用癌症杂志，2018，33（2）：177-180.
[20] 彭彦，王燕，李峻岭，等.血清NSE、ProGRP和LDH在小细胞肺癌诊断治疗中的作用[J].中国肺癌杂志，2016， 19（9）：590-594.
[21] 王丹丹，朱丹燕，王丹，等.BIX-01294靶向组蛋白甲基转移酶G9a在小细胞肺癌患者中的应用研究[J].中国现代医生，2017，55（4）：1-4，封3.
[22] 滕悦，袁成，朱爱玲.血清ProGRP和NSE在小细胞肺癌化疗疗效评价中的应用价值[J].临床和实验医学杂志，2017，16（24）：2440-2442. |
|
|
|
